BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25682546)

  • 21. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients.
    Candal-Pedreira C; Ruano-Ravina A; Calvo de Juan V; Cobo M; Trigo JM; Rodríguez-Abreu D; Estival A; Carcereny E; Cucurull M; López Castro R; Medina A; García Campelo R; Cordeiro González P; Sánchez-Gastaldo A; Bosch-Barrera J; Massutí B; Dómine M; Camps C; Ortega AL; Sánchez-Hernández A; Guirado Risueño M; Del Barco Morillo E; Garrido Fernández A; Provencio M
    Arch Bronconeumol; 2024 Feb; 60(2):88-94. PubMed ID: 38160163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and progression of pre-/minimally invasive lung adenocarcinoma harboring
    Deng C; Chen Z; Bai J; Fu F; Wang S; Li Y; Zhang Y; Chen H
    Transl Lung Cancer Res; 2023 Dec; 12(12):2440-2447. PubMed ID: 38205201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Precision medicine and actionable alterations in lung cancer: A single institution experience.
    Mambetsariev I; Wang Y; Chen C; Nadaf S; Pharaon R; Fricke J; Amanam I; Amini A; Bild A; Chu P; Erhunmwunsee L; Kim J; Munu J; Pillai R; Raz D; Sampath S; Vora L; Qiu F; Smith L; Batra SK; Massarelli E; Koczywas M; Reckamp K; Salgia R
    PLoS One; 2020; 15(2):e0228188. PubMed ID: 32045431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Tissue and Liquid Biopsy in the Clinical Management of Adult Lung Cancer Patients in King Abdul-Aziz Medical City in Riyadh, Saudi Arabia.
    Alanazi L; Alqahtani RN; Masud N; Zuraie MM; Bin Afif AA; Alanazi SH
    Cureus; 2022 Jan; 14(1):e20914. PubMed ID: 35004079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of Radiometabolic Biomarkers to KRAS Mutation Status and ALK Rearrangements in Cases of Lung Adenocarcinoma.
    Aras G; Kanmaz ZD; Tuncay E; Çetinkaya E; Yentürk E; Kocatürk C; Öz B; Çermik TF; Purisa S
    Tumori; 2017 Jan; ():tj5000695. PubMed ID: 29781772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib.
    Thomas D; Maloney ME; Raval G
    Cureus; 2023 Nov; 15(11):e48122. PubMed ID: 38046784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salvage pemetrexed for brain metastases from ALK-positive lung cancer after Gamma Knife radiosurgery: illustrative case.
    Noda R; Akabane A; Kawashima M; Segawa M; Tsunoda S; Inoue T
    J Neurosurg Case Lessons; 2024 Mar; 7(11):. PubMed ID: 38467041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ALK-rearranged CD30-positive poorly differentiated lung adenocarcinoma, mimicking anaplastic large-cell lymphoma.
    George GV; Wallace DS; Wang Y; Carney J; Elsadawi M; Burack WR; Evans AG; Barr PM; Velez MJ; El Hussein S
    Histopathology; 2024 Apr; 84(5):900-902. PubMed ID: 38032068
    [No Abstract]   [Full Text] [Related]  

  • 29. Identification of
    Aktaş TÇ; Kızmazoğlu D; Aktaş S; Gökbayrak ÖE; Serinan E; Erol A; Altun Z; Yuan H; Olgun HN
    Technol Cancer Res Treat; 2023; 22():15330338231211138. PubMed ID: 37964559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of granulocyte colony-stimulating factor producing lung adenocarcinoma with anaplastic lymphoma kinase gene rearrangements.
    Choi KJ; Kim KC; Kim EJ
    Respir Med Case Rep; 2023; 46():101885. PubMed ID: 38222868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy.
    Mesquita FP; Lima LB; Silva ELD; Souza PFN; Moraes MEA; Burbano RMR; Montenegro RC
    Curr Protein Pept Sci; 2024 Feb; ():. PubMed ID: 38424421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma.
    Davidsson E; Murgia N; Ortiz-Villalón C; Wiklundh E; Sköld M; Kölbeck KG; Ferrara G
    Multidiscip Respir Med; 2017; 12():16. PubMed ID: 28560038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology.
    Patil T; Nie Y; Aisner DL; Camidge DR
    Front Oncol; 2021; 11():788245. PubMed ID: 35070994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer.
    Lian W; Ouyang Y
    Oncol Lett; 2017 May; 13(5):3415-3422. PubMed ID: 28521447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and Therapeutic Characteristics of Hospitalized Patients with Advanced Lung Cancer in Najran, Saudi Arabia: A Retrospective Study.
    Badheeb AM; Obied HY; Al Suleiman M; Qurayshah MA; Awad MA; Abu Bakar A; Alwadai B; Nasher AM; Seada IA; Alyami NH; Aman AA; Ahmed F; Al Qasim A; Badheeb M
    Cureus; 2024 Apr; 16(4):e58602. PubMed ID: 38770472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coexistence of a novel intergenic (between CHST2 and SLC9A9)-ALK, TNIK-ALK double-fusion in resected lung adenocarcinoma.
    Liu Z; Huang K; Wu Q; Zhou Q
    Asian J Surg; 2024 Mar; 47(3):1505-1507. PubMed ID: 38071095
    [No Abstract]   [Full Text] [Related]  

  • 37. Solitary acrometastasis of the phalanx as initial presentation of an oligometastatic Kirsten rat sarcoma viral oncogene homolog-mutated lung adenocarcinoma: a case report.
    Pușcașu AI; Moinard-Butot F; Antoni D; Schott R; Somme L
    J Med Case Rep; 2023 Sep; 17(1):395. PubMed ID: 37718451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired double-anaplastic lymphoma kinase rearrangement in lung adenocarcinoma after systemic chemotherapy.
    Zhang J; Li H; Kong F
    Panminerva Med; 2024 Mar; ():. PubMed ID: 38512344
    [No Abstract]   [Full Text] [Related]  

  • 39. First-line crizotinib in ALK-positive lung cancer.
    Alkan A; Köksoy EB; Utkan G
    N Engl J Med; 2015 Feb; 372(8):781-2. PubMed ID: 25693023
    [No Abstract]   [Full Text] [Related]  

  • 40. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
    Park S; Keam B; Kim SH; Kim KH; Kim YJ; Kim JS; Kim TM; Lee SH; Kim DW; Lee JS; Heo DS
    Cancer Res Treat; 2015 Oct; 47(4):630-7. PubMed ID: 25687850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.